-+ 0.00%
-+ 0.00%
-+ 0.00%

Seres Therapeutics Announces Positive Phase 1b Data for SER-155 in Reducing Bloodstream Infections in Allogeneic Stem Cell Transplant Patients, Plans Phase 2 Trial

Reuters·10/14/2025 11:01:08

Please log in to view news